|
|
Volumn 149, Issue 25-26, 2007, Pages 41-43
|
|
Glucagon-like peptide 1 (GLP-1);Neuer therapieansatz bei typ-2-diabetes: Können inkretin-mimetika den beginn der insulintherapie hinauszögern?
|
|
Author keywords
Diabetes; Glucagon like peptide 1
|
|
Indexed keywords
EXENDIN 4;
GLUCAGON;
GLUCAGON LIKE PEPTIDE 1;
GLUCAGON LIKE PEPTIDE 1 RECEPTOR;
GLUCOSE;
HEMOGLOBIN A1C;
INCRETIN;
INSULIN;
ANTIDIABETIC AGENT;
DRUG DERIVATIVE;
LIRAGLUTIDE;
PEPTIDE;
VENOM;
APPETITE;
CLINICAL STUDY;
CONFERENCE PAPER;
DIET RESTRICTION;
FOOD INTAKE;
GLUCAGON RELEASE;
GLUCOSE BLOOD LEVEL;
HUMAN;
INSULIN RELEASE;
NAUSEA;
NON INSULIN DEPENDENT DIABETES MELLITUS;
STOMACH MOTILITY;
WEIGHT REDUCTION;
ARTICLE;
BLOOD;
CLINICAL TRIAL;
DELAYED RELEASE FORMULATION;
DRUG COMBINATION;
METABOLISM;
PHYSIOLOGY;
SUBCUTANEOUS DRUG ADMINISTRATION;
BLOOD GLUCOSE;
CLINICAL TRIALS;
DELAYED-ACTION PREPARATIONS;
DIABETES MELLITUS, TYPE 2;
DRUG THERAPY, COMBINATION;
GLUCAGON-LIKE PEPTIDE 1;
HUMANS;
HYPOGLYCEMIC AGENTS;
INJECTIONS, SUBCUTANEOUS;
INSULIN;
PEPTIDES;
VENOMS;
|
|
EID: 35348864390
PISSN: 14383276
EISSN: None
Source Type: Journal
DOI: 10.1007/bf03365101 Document Type: Conference Paper |
|
Times cited : (13)
|
|
References (0)
|
